Sign up to save your podcasts
Or
Share In spite of plummeting valuation, 23andMe still aims to pivot into biotech
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
In spite of plummeting valuation, 23andMe still aims to pivot into biotech
23andMe has seen its valuation plummet from $6 billion to close to zero, with the Nasdaq threatening to delist the company’s stock. Still, company leaders have high hopes for medical research and a pivot to biotech. Rolfe Winkler has been writing about what happened for The Wall Street Journal, and discussed the company’s financial woes and future roadmap with Marketplace’s Lily Jamali.
View all episodes
By Marketplace
4.4
7171 ratings
23andMe has seen its valuation plummet from $6 billion to close to zero, with the Nasdaq threatening to delist the company’s stock. Still, company leaders have high hopes for medical research and a pivot to biotech. Rolfe Winkler has been writing about what happened for The Wall Street Journal, and discussed the company’s financial woes and future roadmap with Marketplace’s Lily Jamali.
More shows like Marketplace Tech
View all
Marketplace Tech
1,264 Listeners
WSJ Tech News Briefing
1,639 Listeners
Marketplace Morning Report
881 Listeners
Marketplace
8,647 Listeners
Planet Money
30,928 Listeners
Marketplace All-in-One
1,356 Listeners
Composers Datebook
10 Listeners
Piano Puzzler
38 Listeners
Make Me Smart
5,498 Listeners
Bold Names
1,446 Listeners
The Indicator from Planet Money
9,542 Listeners
This Is Uncomfortable
3,595 Listeners
Hard Fork
5,425 Listeners
How We Survive
1,323 Listeners
Financially Inclined
82 Listeners
Everybody in the Pool
221 Listeners
WSJ's Take On the Week
133 Listeners